A preclinical study by researchers at Baylor College of Medicine has uncovered a mechanism that allows triple-negative breast cancer (TNBC) to develop resistance to immune checkpoint blockade (ICB) immunotherapy and to chemotherapy. The study, including tests in mouse models, showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression.  (GenEng News - read more)